Gene Expression of Vascular Endothelial Growth Factor A, Thymidylate Synthase, and Tissue Inhibitor of Metalloproteinase 3 in Prediction of Response to Bevacizumab Treatment in Colorectal Cancer Patients

2011 ◽  
Vol 54 (8) ◽  
pp. 1026-1035 ◽  
Author(s):  
Toshiaki Watanabe ◽  
Takashi Kobunai ◽  
Yoko Yamamoto ◽  
Keiji Matsuda ◽  
Soichiro Ishihara ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colorectal Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Thymidylate Synthase ◽  
Tissue Inhibitor Of Metalloproteinase ◽  
Vascular Endothelial ◽  
Prediction Of Response ◽  
Bevacizumab Treatment ◽  
Colorectal Cancer Patients ◽  
Endothelial Growth Factor

Preoperative Vascular Endothelial Growth Factor Levels as a Prognostic Marker for Stage II or III Colorectal Cancer Patients

2011 ◽  
Vol 4 ◽  
pp. CGM.S7113 ◽  
Author(s):  
Ozgur Kemik ◽  
Ahu Sarbay Kemik ◽  
Aziz Sümer ◽  
Sevim Purisa ◽  
A. Cumhur Dulger ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Stage Ii ◽  
Vascular Endothelial ◽  
Poor Survival ◽  
Colorectal Cancer Patients ◽  
Endothelial Growth Factor

Background The aim of the present study was to determine whether serum vascular endothelial growth factor (VEGF) can provide prognostic information independent of carcinoembryonic antigen levels in patients undergoing curative surgery. Methods Serum samples were collected from 158 patients with colorectal cancer and from 100 controls. Serum and tissue levels of VEGF were measured by enzyme-linked immunosorbent assay. Serum VEGF levels in colorectal cancer patients were compared with those in healthy controls, and we retrospectively assessed the association between serum VEGF levels and clinicopathologic findings and survival. Results VEGF expression was significantly higher in colorectal cancer tissue compared with nontumor tissue. Mean serum VEGF levels in patients were significantly higher than those in controls, and significantly higher in patients with large tumors, lymph node involvement, and distant metastases. Conclusion Elevated serum VEGF was significantly associated with poor survival, but was only an independent risk factor for poor survival in Stage II and/or III disease. Elevated serum VEGF is significantly associated with development of colorectal cancer, and lymph or distant invasive phenotypes and survival, especially in Stage II and III patients.

Significance of monitoring vascular endothelial growth factor signals in blood during treatment of colorectal cancer patients.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e15563-e15563
Author(s):  
Nao Kakizawa ◽  
Koichi Suzuki ◽  
Hideki Ishikawa ◽  
Fumiaki Watanabe ◽  
Fumi Hasegawa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Vascular Endothelial ◽  
Colorectal Cancer Patients ◽  
Endothelial Growth Factor

Inhibition of Vascular Endothelial Growth Factor by Octreotide in Colorectal Cancer Patients

2001 ◽  
Vol 19 (1) ◽  
pp. 8-12 ◽  
Author(s):  
Stefano Cascinu ◽  
Elena Del Ferro ◽  
Marco Ligi ◽  
Maria Pia Staccioli ◽  
Paolo Giordani ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Vascular Endothelial ◽  
Colorectal Cancer Patients ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document